MIT and Novo Nordisk researchers have developed a capsule that lets patients receive medications without injections. MIT News ...
With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...
The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of Denmark after cashing in on the weight-loss drug boom. The Novo Nordisk ...
The needle device market is forecast to grow to over $6.8bn by 2033, according to analysis by GlobalData. Novo Nordisk’s investor relations manager David Heiberg Landsted confirmed the current ...
Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.
Danish pharmaceutical company Novo Nordisk has launched its mega-popular weight loss drug Wegovy in China — and it's charging just a tiny fraction of what the blockbuster drug costs in the US.
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other profitable European stocks. After the U.S. Presidential elections, the global economies ...
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other most promising healthcare stocks according to hedge funds. The healthcare sector depends on ...
With most autoinjectors designed to be disposable or at least with disposable ... so a new initiative by Novo Nordisk to recycle pre-filled injection pens used by people living with diabetes ...
1 Day NVO -0.05% DJIA -0.24% S&P 500 -0.34% Health Care/Life Sciences 1.92% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...